Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 268.21B P/E 20.64 EPS this Y 466.90% Ern Qtrly Grth -
Income 365M Forward P/E 13.76 EPS next Y 14.10% 50D Avg Chg -4.00%
Sales 60.12B PEG 0.22 EPS past 5Y -11.64% 200D Avg Chg -3.00%
Dividend 3.00% Price/Book 5.73 EPS next 5Y 67.56% 52W High Chg -12.00%
Recommedations 1.80 Quick Ratio 0.73 Shares Outstanding 2.53B 52W Low Chg 25.00%
Insider Own 0.05% ROA 2.64% Shares Float 2.53B Beta 0.40
Inst Own 78.57% ROE 0.90% Shares Shorted/Prior 19.59M/16.60M Price 105.70
Gross Margin 73.53% Profit Margin 0.61% Avg. Volume 7,449,562 Target Price 137.02
Oper. Margin 0.08% Earnings Date Apr 25 Volume 10,865,850 Change 0.40%
About Merck & Company, Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Merck & Company, Inc. News
06:00 AM Merck Insiders Sold US$15m Of Shares Suggesting Hesitancy
04/15/24 10 Best Low Volatility ETFs To Buy
04/11/24 Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?
04/10/24 Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
04/10/24 Company News for Apr 10, 2024
04/08/24 Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement
04/07/24 The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
04/06/24 10 Best Weight Loss Drug Stocks to Buy Now
04/06/24 The three-year decline in earnings for Merck NYSE:MRK) isn't encouraging, but shareholders are still up 93% over that period
04/05/24 Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
04/04/24 Merck puts KRAS cancer drug competitor to the test
04/04/24 Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
04/03/24 Merck (MRK) Stock Sinks As Market Gains: What You Should Know
04/03/24 REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
04/01/24 Why Merck (MRK) is a Top Momentum Stock for the Long-Term
04/01/24 Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
03/29/24 3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List
03/29/24 Merck & Co., Inc.'s (NYSE:MRK) Intrinsic Value Is Potentially 98% Above Its Share Price
03/28/24 Merck (MRK) Rises Higher Than Market: Key Facts
03/28/24 Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
MRK Chatroom

User Image MrPHD_Certifed Posted - 57 minutes ago

$SLS $MRK $BMY $ABBV Who is going to buy us out?

User Image maker11 Posted - 2 hours ago

@AndersKingern_ @GPS_OS_21_vs_SOC_5 @MrPHD_Certifed $MRK had 22,123 “watchers”. That’s right: almost half as much as $SLS. Makes sense 🥸

User Image MacroVue Posted - 7 hours ago

$MRK Let’s bounce! Should be an earnings run up. Will be very strong Keytruda and Gardasil sales. Robust pipeline!

User Image mikeywo Posted - 11 hours ago

$PDSB I’m ready for a complete buyout of PDSB by $MRK for 6- 700M. Obviously the SP and MC doesn’t align with the data and all the programs that are running. But at this point there is no path fwd for the company to run even one ph3 trial. So there is no path to commercial approval without some incredibly lucrative partnership which doesn’t look good. They should Just come up with a fair value for versamune and pdsadc and the ongoing trials and just end this never ending waffling , delaying and bullshitting the shareholders.

User Image Jackie_O_ Posted - 1 day ago

$VKTX $MRK ?? 😁

User Image Aigner_Andreas Posted - 1 day ago

TD BUY $MRK at 126.19, Supp 125.52 Resis 131.95 R5 HiLo 83% T1Y 105 buy 2.2 DIV 2.82% #Merck & Co #stocks #trading #finance #market

User Image WhisperNumber Posted - 2 days ago

$JNJ #earnings before open Tues, the expectation from the WhisperNumber community is $2.80, 16c ahead of analyst estimates. Earnings came in $0.09 short of the whisper last quarter. 60% beat rate. Implied movement +/-2.6%. https://whispernumber.com/wr_options_alerts.jsp #options $MRK $AZN

User Image MuscleStocks Posted - 2 days ago

$MRK Bounce off the 50 day

User Image thayford Posted - 2 days ago

Long $MRK 5/31 128c

User Image BretKenwell Posted - 2 days ago

Trimming was the right move into the $130s, but $MRK looking interesting again. Stock continues to hold up after the pullback to the 21-day & 50-day sma, 50% retrace and gap-fill level. If nothing else, a clear-cut Risk/Reward for active traders! Daily & Weekly view:

User Image Teleboy Posted - 2 days ago

$AIM With the uptick in message traffic and many recent updates I will try to post this twice a week: *10K and CEO presentations very positive (esp. the ovarian cancer updates) *Insider buying from three directors and the COO. *Excellent interim data from the combo $AZN Pancreatic trial and the combo $MRK UPitt recurrent Ovarian; other positive updates from TNBC, Melanoma, and Pancreatic trials. Waiting to hear: 1. Detailed UPitt ovarian cancer data update due Q2 NCT03734692 (phase 1 and 2) 2. Takeover/licensing negotiations progress 3. TNBC final trial results with Keytruda and Celebrex $PFE NCT03599453 (phase 1) Study completed March 2023 and results could be anytime 4. US pancreatic 1st dose (updated start date now May 2024)

User Image GPS_OS_21_vs_SOC_5 Posted - 2 days ago

$SLS @Wut_About_Bob as a matter of fact in the Ph2 Gps Keytruda $MRK published abstract trial for advanced, platinum resistant/refractroy ovarain cancer patients, the Memorial Sloan Kettering and Merck Doctors said Gps immunotherapy was directly correlated to increased survival, (13 months w Key alone vs 18.4 w Gps - obviously they see Gps working) and Gps would work even better in a Remission maintenance setting - like the current P3, imminently due P3. note: elahere was approved in this same setting proc w 16.4 months of os, $IMGN and got bought for 10.1b. $MRK / $BMY will be paying a premium for a deRisked Gps once the P3 is In, any day now.

User Image MrPHD_Certifed Posted - 2 days ago

$SLS $MRK $BMY Phase 3 Interim worth hundreds of millions We are partnered with two big pharma companies

User Image Avocado_smash Posted - 2 days ago

$LLY $JNJ $MRK $ABBV $PFE BMY Large Pharma Dividend Stock:

User Image MYA_Markets Posted - 3 days ago

$SPY is real strike back in 48hrs. Great time to buy puts 6 month out. I target ALL airlines 2 weeks ago and $MRK and $GE and ALL banks. Now spy and eBay and Lyft is next.

User Image Maverick11 Posted - 3 days ago

$RARE Why the move forward a day for the update … and after this weekend? Expecting great news and a big move nevertheless. $10-20+. That said with my luck definitive confirm that $VKTX in talks with $PFE or $MRK also after this weekend … that update is any minute. Mav

User Image JuanValdex Posted - 4 days ago

$POAI $MRK $LLY " fujjfilm- investigational development. "

User Image GemsBot Posted - 4 days ago

8 of 11 $MRK $MSFT $NKE Experienced traders are also using tick, volume, range or price change intervals to suit their own trading profile … see 9/11

User Image FE123 Posted - 5 days ago

$IOVA $MRK Spend that $15 Billion on $IOVA

User Image Samishere Posted - 5 days ago

$MRK Hey, aren’t you MRK longs shaking in your boots over the CHRS PD-1 inhibitor, Tori ? The super duper Chinese license they got FDA approved! Gonna steal big market share ,, eh ?

User Image Teleboy Posted - 5 days ago

$AIM Happy Friday and recent updates: *10K and CEO presentations very positive (esp. the ovarian cancer updates) *Insider buying from three directors and the COO. *Excellent interim data from the combo $AZN Pancreatic trial and the combo $MRK UPitt recurrent Ovarian; other positive updates from TNBC, Melanoma, and Pancreatic trials. Waiting to hear: 1. Detailed UPitt ovarian cancer data update due Q2 NCT03734692 (phase 1 and 2) 2. Takeover/licensing negotiations progress. 3. TNBC final trial results with Keytruda and Celebrex $PFE NCT03599453 (phase 1) 4. US pancreatic 1st dose (updated start date now May 2024) Have a great weekend.

User Image Teleboy Posted - 5 days ago

$AIM Reminder, almost six months since Azenova LLC were hired to find a deal. "They're experts in moving drugs into oncology licensing agreement, and IF the people that we are working with now [ $MRK and $AZN ] are not interested in moving forward, there are other companies...." https://finance.yahoo.com/news/aim-immunotech-engages-business-development-124500982.html

User Image Tyrus4real Posted - 5 days ago

$ALLR going to get bought by $MRK for their drug stenoparib, it is showing positive results for advanced ovarian cancer

User Image TrustButVerifi Posted - 5 days ago

$VKTX @DougKass I just placed $VKTX long on my @realmoney Best Idea List. $74.40 (down from $99 in late Feb/early March) @dougkass https://pro.thestreet.com/dougs-daily-diary/2024-04-02#viking-therapeutics-move… It seems the company is a logical fit to be acquired by $JNJ, $MRK, $PFE or $LLY. Bookmark this tweet!

User Image BioRich Posted - 5 days ago

$MRK hoping to finish strong and hope they acquire $TERN $TRIV or $MLTX to expand their already robust portfolio.

User Image R_NW Posted - 6 days ago

$IOVA I knew the $MRNA & $MRK PR this week was a head fake, it will take years to have an FDA approved Melanoma and small cell vaccine, AND the cost would be prohibitive. AND who needs a vaccine if TIL will cure you in one shot?

User Image Jubileespirit Posted - 6 days ago

$AIM $AZN $BMY $MRK $PFE

User Image Teleboy Posted - 6 days ago

$AIM Yesterday's positive news also mentioned combo TNBC and Colorectal cancer trials. The TNBC interim results from Roswell Park Comprehensive Cancer Center is where a patient's body shed the tumor itself (auto-amputation). The video is 48 seconds. TNBC combo trial with Keytruda $MRK and Celebrex $PFE NCT03599453 (phase 1) Reposted due to large message volume Dr Kalinski: https://www.youtube.com/watch?v=qu4YaC1Ts1M

User Image Teleboy Posted - 6 days ago

$AIM With the big increase in message volume after the great news from the recurrent ovarian combo trial, here is a reminder of current or recent combo trials: *Phase 1 and 2: Ampligen and Keytruda ($MRK) for Ovarian Cancer (This was the one with "spectacular" preliminary data) *Phase 1b/2 in Europe for Pancreatic in combo with Imfinzi ($AZN) *Phase 2: Ampligen and Celecoxib ($PFE) for Colorectal Cancer (Completed: positive data) *Phase 1 Ampligen, Celecoxib and Keytruda for TNBC (Completed, excellent preliminary data) *Phase 1 Ampligen, Celecoxib and Paclitaxel ($BMY) for TNBC (Completed, excellent results) *Phase 2: Ampligen and Celecoxib for Melanoma *Phase 1 and 2: Ampligen, Celecoxib and Keytruda for TNBC

User Image taxplanr Posted - 1 week ago

Wasn't that an interesting pump I mean pr done by $MRNA with Keytruda but not done by $MRK?

Analyst Ratings
Berenberg Buy Apr 8, 24
Cantor Fitzgerald Overweight Apr 5, 24
Cantor Fitzgerald Overweight Apr 1, 24
Truist Securities Buy Mar 28, 24
Cantor Fitzgerald Overweight Mar 27, 24
Wells Fargo Equal-Weight Mar 27, 24
Societe Generale Sell Mar 11, 24
Cantor Fitzgerald Overweight Mar 11, 24
Cantor Fitzgerald Overweight Feb 29, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Oosthuizen Johannes Jacobus President, U.S. Mark.. President, U.S. Market Nov 09 Sell 102.3841 2,081 213,061 18,191 11/13/23
DeLuca Richard R. EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth Nov 08 Sell 105.0286 43,823 4,602,668 111,764 11/09/23
Oosthuizen Johannes Jacobus President, U.S. Mark.. President, U.S. Market Oct 30 Option 102.82 915 94,080 20,723 10/31/23
Davis Robert M Chairman, CEO & Pres.. Chairman, CEO & President Apr 28 Sell 114.93 143,329 16,472,802 271,817 04/28/23
Davis Robert M Chairman, CEO & Pres.. Chairman, CEO & President Apr 28 Option 56.04 143,329 8,032,157 415,146 04/28/23
Chattopadhyay Sanat Exe V-P & Pres. MMD Exe V-P & Pres. MMD Apr 13 Sell 115.07 134,055 15,425,709 04/14/23
Chattopadhyay Sanat Exe V-P & Pres. MMD Exe V-P & Pres. MMD Apr 13 Option 59.06 134,055 7,917,288 134,055 04/14/23
Romanelli Joseph President, Human Hea.. President, Human Health Int?l Feb 15 Sell 108.2201 5,000 541,100 20,284 02/16/23
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Feb 13 Sell 109.1003 1,815 198,017 33,085 02/14/23
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Feb 09 Sell 107.0013 5,000 535,006 34,900 02/10/23
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Feb 06 Sell 104.2546 4,436 462,473 39,900 02/08/23
Oosthuizen Johannes Jacobus President, U.S. Mark.. President, U.S. Market Nov 09 Sell 103.21 1,795 185,262 16,731 11/10/22
Davis Robert M CEO & President CEO & President Nov 09 Option 0 167,613 415,206 11/10/22
Davis Robert M CEO & President CEO & President Nov 09 Sell 102.84 167,613 17,237,321 247,593 11/10/22
FRAZIER KENNETH C Executive Chair Executive Chair Nov 07 Option 0 235,769 936,422 11/08/22
FRAZIER KENNETH C Executive Chair Executive Chair Nov 07 Sell 99.31 235,769 23,414,219 700,653 11/08/22
Oosthuizen Johannes Jacobus SVP, U.S. Market SVP, U.S. Market May 03 Option 87.1 907 79,000 14,961 05/05/22
Garay Arpa SVP Human Health Glo.. SVP Human Health Global Mktg. May 03 Option 87.1 907 79,000 2,368 05/05/22
Karachun Rita A Sr. VP Fince-Global.. Sr. VP Fince-Global Controller May 03 Option 87.1 949 82,658 41,429 05/05/22
Klobuchar Michael A EVP - Chief Strategy.. EVP - Chief Strategy Officer May 03 Option 87.1 885 77,084 15,775 05/05/22
LeCointe-Cephas Lisa SVP Chief Ethics & C.. SVP Chief Ethics & Com Officer May 03 Option 87.1 813 70,812 3,943 05/05/22
Litchfield Caroline EVP & CFO EVP & CFO May 03 Option 87.65 773 67,753 27,799 05/04/22
Li Dean Y Executive VP & Presi.. Executive VP & President, MRL May 03 Option 87.65 773 67,753 16,839 05/04/22
Williams David Michael EVP,Chief Info&Digit.. EVP,Chief Info&Digital Officer May 03 Option 87.65 427 37,427 9,410 05/04/22
Williams David Michael EVP,Chief Info&Digit.. EVP,Chief Info&Digital Officer Feb 10 Option 76.53 1,202 91,989 7,421 02/14/22
Clyburn Frank EVP & Pres ? Human H.. EVP & Pres ? Human Health Oct 30 Option 29.35 42,120 1,236,222 136,857 11/02/21
Clyburn Frank EVP & Pres ? Human H.. EVP & Pres ? Human Health Oct 30 Sell 87.87 39,762 3,493,887 97,095 11/02/21
DeLuca Richard R. EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth Oct 29 Option 0 135,405 252,335 11/02/21
DeLuca Richard R. EVP&Pres, Merck Anim.. EVP&Pres, Merck Animal Heallth Oct 29 Sell 87.56 135,405 11,856,062 116,930 11/02/21
Karachun Rita A Sr. VP Fince-Global.. Sr. VP Fince-Global Controller May 06 Option 75.98 1,212 92,088 36,215 05/06/21
LeCointe-Cephas Lisa SVP Chief Ethics & C.. SVP Chief Ethics & Com Officer May 06 Option 75.98 694 52,730 2,612 05/06/21
MIZELL STEVEN EVP, Chief HR Office.. EVP, Chief HR Officer Nov 03 Option 75.89 4,574 347,121 7,624 11/03/20
Davis Robert M EVP, Global Svcs & C.. EVP, Global Svcs & CFO Oct 06 Option 0 251,273 422,329 10/06/20
Davis Robert M EVP, Global Svcs & C.. EVP, Global Svcs & CFO Oct 06 Sell 81.03 251,273 20,360,651 171,056 10/06/20